)

Baxter International (BAX) investor relations material
Baxter International Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Q2 2025 sales from continuing operations grew 4% reported and 1% operational, with all segments contributing to growth.
Adjusted EPS from continuing operations was $0.59, up 28% year-over-year, at the low end of guidance.
Sale of Kidney Care business completed in January 2025, generating $3.3B net after-tax proceeds and reported as discontinued operations.
New CEO Andrew Hider appointed, expected to start by September 2025, to drive innovation and growth.
Inventory levels restored post-Hurricane Helene, with IV solutions allocations removed.
Financial highlights
Q2 2025 global sales: $2.81B, up 4% year-over-year; H1 2025 sales: $5.44B, up 5%.
Adjusted operating margin was 15.1% in Q2 2025, up 180 bps year-over-year.
Adjusted gross margin for Q2 2025 was 40.7%, down from 42.4% prior year; GAAP gross margin was 35.3%.
Net income from continuing operations was $122M in Q2 2025, up 28% year-over-year.
Free cash flow for H1 2025 was $(144)M; Q2 2025 was $77M positive.
Outlook and guidance
Full-year 2025 sales growth expected at 6%-7% reported, 3%-4% operational; adjusted EPS guidance is $2.42–$2.52.
Third-quarter 2025 sales growth expected at 6%-7% reported, 3%-4% operational; adjusted EPS $0.58–$0.62.
Full-year adjusted operating margin expected between 15% and 16%.
Guidance reflects downside risks from NOVUM pump pause, IV fluid conservation, and macroeconomic uncertainty.
Segment operational growth guidance for FY 2025: Medical Products & Therapies 3%-4%, Healthcare Systems & Technologies 3%-4%, Pharmaceuticals 4%-5%.
Next Baxter International earnings date

Next Baxter International earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Experts in Chronic Diseases
Baxter International Inc. is an American healthcare company with global operations. The company has a focus on kidney disease and various chronic illnesses. Baxter International operates under two different segments: BioScience and Medical Products. The first of these two produces various medications, while the latter provides equipment and products used for the treatment of patients in hospitals and care facilities. The company is headquartered in Deerfield, Illinois, and its shares trade on the NYSE.
The History
Founded in 1931 by Dr. Donald Baxter, Baxter International Inc. was initiated as a small enterprise manufacturing and distributing intravenous (IV) therapy solutions. Over its history, the company has expanded significantly, evolving into a global healthcare leader providing a wide array of medical products and services crucial for patient care. Baxter has been particularly influential in renal care, nutritional therapies, advanced surgical technologies, and critical care products. Companies operating in a similar field include names like Abbott Laboratories, Medtronic, and Fresenius Medical Care.
BioScience
Baxter BioScience is a division of Baxter International Inc. that specializes in the research, development, and production of biopharmaceuticals. The division produces a range of products for the treatment of hemophilia and other bleeding disorders. These include clotting factor replacements, which are proteins typically missing or deficient in patients with hemophilia. By providing these therapies, Baxter BioScience assists patients in managing and mitigating bleeding events.
In addition, the division manufactures immunoglobulin therapies. These are employed in the treatment of immune deficiencies and other autoimmune diseases. By supplying patients with a regular source of the necessary antibodies, these therapies can help modulate or supplement the patient's immune system.
Medical Products
The Medical Products division specializes in the development and distribution of essential medical devices and pharmaceuticals used across various healthcare settings.
One of its core product areas is renal care. Baxter offers a comprehensive range of products for peritoneal dialysis and hemodialysis. Examples include PD cyclers, solutions, and related consumables, which help patients with chronic kidney disease manage their condition.
Additionally, Baxter Medical Products provides intravenous (IV) therapies, systems, and administrative sets. These IV products range from basic saline solutions to more specialized medications. They are integral to hospitals, clinics, and other medical facilities for delivering fluids, medications, and nutrients directly into patients' veins. The division also offers products for parenteral nutrition, assisting patients who cannot consume food normally. These nutritional products are formulated to meet specific dietary needs and are delivered intravenously. Moreover, Baxter Medical Products provides various infusion pumps and systems.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage